Pleiotropic effects of vitamin D in chronic kidney disease

Wen Chih Liu, Chia Chao Wu, Yao Min Hung, Min Tser Liao, Jia Fwu Shyu, Yuh Feng Lin, Kuo Cheng Lu, Kun Chieh Yeh

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Low 25(OH)D levels are common in chronic kidney disease (CKD) patients and are implicated in all-cause mortality and morbidity risks. Furthermore, the progression of CKD is accompanied by a gradual decline in 25(OH)D production. Vitamin D deficiency in CKD causes skeletal disorders, such as osteoblast or osteoclast cell defects, bone turnover imbalance, and deterioration of bone quality, and nonskeletal disorders, such as metabolic syndrome, hypertension, immune dysfunction, hyperlipidemia, diabetes, and anemia.Extra-renal organs possess the enzymatic machinery for converting 25(OH)D to 1,25(OH)2D, which may play considerable biological roles beyond the traditional roles of vitamin D. Pharmacological 1,25(OH)2D dose causes hypercalcemia and hyperphosphatemia as well as adynamic bone disorder, which intensifies vascular calcification. Conversely, native vitamin D supplementation reduces the risk of hypercalcemia and hyperphosphatemia, which may play a role in managing bone and cardio-renal health and ultimately reducing mortality in CKD patients. Nevertheless, the combination of native vitamin D and active vitamin D can enhance therapy benefits of secondary hyperparathyroidism because of extra-renal 1α-hydroxylase activity in parathyroid gland. This article emphasizes the role of native vitamin D replacements in CKD, reviews vitamin D biology, and summarizes the present literature regarding native vitamin D replacement in the CKD population.

Original languageEnglish
Pages (from-to)1-12
Number of pages12
JournalClinica Chimica Acta
Volume453
DOIs
Publication statusPublished - Jan 30 2016

Fingerprint

Chronic Renal Insufficiency
Vitamin D
Bone
Hyperphosphatemia
Hypercalcemia
Kidney
Bone and Bones
Vascular Calcification
Secondary Hyperparathyroidism
Parathyroid Glands
Vitamin D Deficiency
Mortality
Bone Remodeling
Osteoclasts
Mixed Function Oxygenases
Hyperlipidemias
Osteoblasts
Medical problems
Anemia
Machinery

Keywords

  • Chronic kidney disease
  • Combination vitamin D therapy
  • Extraskeletal health
  • Skeletal quality
  • Vitamin D

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Liu, W. C., Wu, C. C., Hung, Y. M., Liao, M. T., Shyu, J. F., Lin, Y. F., ... Yeh, K. C. (2016). Pleiotropic effects of vitamin D in chronic kidney disease. Clinica Chimica Acta, 453, 1-12. https://doi.org/10.1016/j.cca.2015.11.029

Pleiotropic effects of vitamin D in chronic kidney disease. / Liu, Wen Chih; Wu, Chia Chao; Hung, Yao Min; Liao, Min Tser; Shyu, Jia Fwu; Lin, Yuh Feng; Lu, Kuo Cheng; Yeh, Kun Chieh.

In: Clinica Chimica Acta, Vol. 453, 30.01.2016, p. 1-12.

Research output: Contribution to journalArticle

Liu, WC, Wu, CC, Hung, YM, Liao, MT, Shyu, JF, Lin, YF, Lu, KC & Yeh, KC 2016, 'Pleiotropic effects of vitamin D in chronic kidney disease', Clinica Chimica Acta, vol. 453, pp. 1-12. https://doi.org/10.1016/j.cca.2015.11.029
Liu, Wen Chih ; Wu, Chia Chao ; Hung, Yao Min ; Liao, Min Tser ; Shyu, Jia Fwu ; Lin, Yuh Feng ; Lu, Kuo Cheng ; Yeh, Kun Chieh. / Pleiotropic effects of vitamin D in chronic kidney disease. In: Clinica Chimica Acta. 2016 ; Vol. 453. pp. 1-12.
@article{16166a4d42e14e1cacf613e4e888a84e,
title = "Pleiotropic effects of vitamin D in chronic kidney disease",
abstract = "Low 25(OH)D levels are common in chronic kidney disease (CKD) patients and are implicated in all-cause mortality and morbidity risks. Furthermore, the progression of CKD is accompanied by a gradual decline in 25(OH)D production. Vitamin D deficiency in CKD causes skeletal disorders, such as osteoblast or osteoclast cell defects, bone turnover imbalance, and deterioration of bone quality, and nonskeletal disorders, such as metabolic syndrome, hypertension, immune dysfunction, hyperlipidemia, diabetes, and anemia.Extra-renal organs possess the enzymatic machinery for converting 25(OH)D to 1,25(OH)2D, which may play considerable biological roles beyond the traditional roles of vitamin D. Pharmacological 1,25(OH)2D dose causes hypercalcemia and hyperphosphatemia as well as adynamic bone disorder, which intensifies vascular calcification. Conversely, native vitamin D supplementation reduces the risk of hypercalcemia and hyperphosphatemia, which may play a role in managing bone and cardio-renal health and ultimately reducing mortality in CKD patients. Nevertheless, the combination of native vitamin D and active vitamin D can enhance therapy benefits of secondary hyperparathyroidism because of extra-renal 1α-hydroxylase activity in parathyroid gland. This article emphasizes the role of native vitamin D replacements in CKD, reviews vitamin D biology, and summarizes the present literature regarding native vitamin D replacement in the CKD population.",
keywords = "Chronic kidney disease, Combination vitamin D therapy, Extraskeletal health, Skeletal quality, Vitamin D",
author = "Liu, {Wen Chih} and Wu, {Chia Chao} and Hung, {Yao Min} and Liao, {Min Tser} and Shyu, {Jia Fwu} and Lin, {Yuh Feng} and Lu, {Kuo Cheng} and Yeh, {Kun Chieh}",
year = "2016",
month = "1",
day = "30",
doi = "10.1016/j.cca.2015.11.029",
language = "English",
volume = "453",
pages = "1--12",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",

}

TY - JOUR

T1 - Pleiotropic effects of vitamin D in chronic kidney disease

AU - Liu, Wen Chih

AU - Wu, Chia Chao

AU - Hung, Yao Min

AU - Liao, Min Tser

AU - Shyu, Jia Fwu

AU - Lin, Yuh Feng

AU - Lu, Kuo Cheng

AU - Yeh, Kun Chieh

PY - 2016/1/30

Y1 - 2016/1/30

N2 - Low 25(OH)D levels are common in chronic kidney disease (CKD) patients and are implicated in all-cause mortality and morbidity risks. Furthermore, the progression of CKD is accompanied by a gradual decline in 25(OH)D production. Vitamin D deficiency in CKD causes skeletal disorders, such as osteoblast or osteoclast cell defects, bone turnover imbalance, and deterioration of bone quality, and nonskeletal disorders, such as metabolic syndrome, hypertension, immune dysfunction, hyperlipidemia, diabetes, and anemia.Extra-renal organs possess the enzymatic machinery for converting 25(OH)D to 1,25(OH)2D, which may play considerable biological roles beyond the traditional roles of vitamin D. Pharmacological 1,25(OH)2D dose causes hypercalcemia and hyperphosphatemia as well as adynamic bone disorder, which intensifies vascular calcification. Conversely, native vitamin D supplementation reduces the risk of hypercalcemia and hyperphosphatemia, which may play a role in managing bone and cardio-renal health and ultimately reducing mortality in CKD patients. Nevertheless, the combination of native vitamin D and active vitamin D can enhance therapy benefits of secondary hyperparathyroidism because of extra-renal 1α-hydroxylase activity in parathyroid gland. This article emphasizes the role of native vitamin D replacements in CKD, reviews vitamin D biology, and summarizes the present literature regarding native vitamin D replacement in the CKD population.

AB - Low 25(OH)D levels are common in chronic kidney disease (CKD) patients and are implicated in all-cause mortality and morbidity risks. Furthermore, the progression of CKD is accompanied by a gradual decline in 25(OH)D production. Vitamin D deficiency in CKD causes skeletal disorders, such as osteoblast or osteoclast cell defects, bone turnover imbalance, and deterioration of bone quality, and nonskeletal disorders, such as metabolic syndrome, hypertension, immune dysfunction, hyperlipidemia, diabetes, and anemia.Extra-renal organs possess the enzymatic machinery for converting 25(OH)D to 1,25(OH)2D, which may play considerable biological roles beyond the traditional roles of vitamin D. Pharmacological 1,25(OH)2D dose causes hypercalcemia and hyperphosphatemia as well as adynamic bone disorder, which intensifies vascular calcification. Conversely, native vitamin D supplementation reduces the risk of hypercalcemia and hyperphosphatemia, which may play a role in managing bone and cardio-renal health and ultimately reducing mortality in CKD patients. Nevertheless, the combination of native vitamin D and active vitamin D can enhance therapy benefits of secondary hyperparathyroidism because of extra-renal 1α-hydroxylase activity in parathyroid gland. This article emphasizes the role of native vitamin D replacements in CKD, reviews vitamin D biology, and summarizes the present literature regarding native vitamin D replacement in the CKD population.

KW - Chronic kidney disease

KW - Combination vitamin D therapy

KW - Extraskeletal health

KW - Skeletal quality

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=84949543490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949543490&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2015.11.029

DO - 10.1016/j.cca.2015.11.029

M3 - Article

C2 - 26656443

AN - SCOPUS:84949543490

VL - 453

SP - 1

EP - 12

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

ER -